Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

May 31, 2009

Conditions
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic Polyneuropathy
Interventions
DRUG

SB-509

60 mg dose

OTHER

Normal Saline

Trial Locations (15)

10022

Peripheral Neuropathy Center, Weill Medical College of Cornell University, New York

12205

Upstate Clinical Research, Albany

16635

Altoona Center for Clinical Research, Duncansville

33136

University of Miami, Diabetes Research Institute, Miami

33351

Neurology Clinical Research, Sunrise

34205

Bradenton Research Center, Bradenton

66160

University of Kansas Medical Center, Kansas City

68131

Creighton Diabetes Center, Omaha

77030

Nerve and Muscle Center of Texas, Houston

78229

DGD Research, San Antonio

90712

Advanced Medical Research, LLC, Lakewood

92037

Coordinated Clinical Research, La Jolla

94109

SF Clinical Research Center, San Francisco

94598

Diablo Clinical Research, Walnut Creek

06700

Instituto Mexicano de Investigación Clinica, Mexico City

All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

Sangamo Therapeutics

INDUSTRY